IP Library Granted Patent US 9,579,321
Granted Patent B2
US 9,579,321 · App. 14/535,690 · Granted Feb 28, 2017

Methods and compositions to reduce oxidative stress

Inventor: Louis M. Messina (Westborough, MA)
Assignee: University of Massachusetts
A61K31/519A61K31/198A61K31/375A61K45/06A61K48/005A61K31/495A61K35/13C12N2799/022C12P13/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,579,321
App. No.
14/535,690
Granted
Feb 28, 2017
Kind
B2
Abstract

The invention relates to therapeutic applications for compositions that reduce the level of oxidative stress on cells in vivo or in vitro. The invention describes methods for improving the therapeutic properties of stem cells. The invention also provides combination therapies that are useful to balance the oxidative microenvironment of cells in vivo or in vitro.

Claims (23)

1. A method of treating Peripheral Arterial Disease (PAD) in a subject, the method comprising identifying a subject who has PAD and administering to the subject active agents consisting of:

a. L-arginine,

b. tetrahydrobiopterin, and

c. ascorbic acid or ascorbate;

wherein the ratio of (a):(b) is 1-30:1; and

wherein the ratio of (b):(c) is 1:0.1-15.

2. The method of claim 1 , comprising administering:

a. L-arginine;

b. tetrahydrobiopterin; and

c. ascorbic acid.

3. The method of claim 1 , comprising administering:

88.5 mg/kg/day L-arginine;

10 mg/kg/day tetrahydrobiopterin; and

88.5 mg/kg/day ascorbic acid or ascorbate.

4. The method of claim 1 , wherein the method comprises administering to the subject a pharmaceutical composition, wherein the active ingredients of the composition consist of:

a. L-arginine,

b. tetrahydrobiopterin, and

c. ascorbic acid or ascorbate;

wherein the ratio of (a):(b) is 1-30:1; and

wherein the ratio of (b):(c) is 1:0.1-15.

5. The method of claim 4 , wherein the pharmaceutical composition is formulated as tablets, capsules, powders, granules, or solutions for oral ingestion.

6. The method of claim 4 , wherein the pharmaceutical composition comprises one or more excipients selected from the group consisting of: hydroxypropyl methylcellulose, sodium carboxymethyl cellulose and polyvinylpyrrolidine.

7. The method of claim 1 , wherein the subject also has diabetes.

Assignments (2)
CONFIRMATORY LICENSE Recorded Oct 30, 2017
From: UNIVERSITY OF MASSACHUSETTS MEDICAL SCH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044317/0198 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2014
From: MESSINA, LOUIS M.
To: UNIVERSITY OF MASSACHUSETTS
Reel/Frame 034353/0573 →
Continuity (4)
Division 13386462
Provisional Application 61357179 · Jun 22, 2010
Provisional Application 61227768 · Jul 22, 2009
Related Publication 20150065514A1 · Mar 5, 2015